Detalhe da pesquisa
1.
A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer.
Gynecol Oncol
; 135(1): 25-33, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-25019569
2.
AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study.
Cancer
; 118(24): 6152-61, 2012 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-22692704
3.
Increasing Participation in Daily Activities among US Adults with Arthritis.
Am J Health Behav
; 43(3): 520-530, 2019 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31046883
4.
Sources of variation in baseline gene expression levels from toxicogenomics study control animals across multiple laboratories.
BMC Genomics
; 9: 285, 2008 Jun 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-18549499
5.
Development of an eHealth System to Capture and Analyze Patient Sensor and Self-Report Data: Mixed-Methods Assessment of Potential Applications to Improve Cancer Care Delivery.
JMIR Med Inform
; 6(4): e46, 2018 Oct 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-30348634
6.
Conserved microRNA characteristics in mammals.
Oligonucleotides
; 16(2): 115-44, 2006.
Artigo
em Inglês
| MEDLINE | ID: mdl-16764537
7.
A Phase I, First-in-Human Study of AMG 780, an Angiopoietin-1 and -2 Inhibitor, in Patients with Advanced Solid Tumors.
Clin Cancer Res
; 22(18): 4574-84, 2016 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27076631
8.
Challenges in developing a validated biomarker for angiogenesis inhibitors: the motesanib experience.
PLoS One
; 9(10): e108048, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-25314641
9.
A phase 1b, open-label study of trebananib plus bevacizumab or motesanib in patients with solid tumours.
Oncotarget
; 5(22): 11154-67, 2014 Nov 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-25525888
10.
A phase I, open-label study of trebananib combined with sorafenib or sunitinib in patients with advanced renal cell carcinoma.
Clin Genitourin Cancer
; 12(3): 167-177.e2, 2014 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-24365125
11.
Sclerostin expression is induced by BMPs in human Saos-2 osteosarcoma cells but not via direct effects on the sclerostin gene promoter or ECR5 element.
Bone
; 49(6): 1131-40, 2011 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-21890009
12.
Phase 1 study of the investigational, oral angiogenesis inhibitor motesanib in Japanese patients with advanced solid tumors.
Cancer Chemother Pharmacol
; 66(5): 935-43, 2010 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-20107802
13.
Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancer.
J Clin Endocrinol Metab
; 95(11): 5018-27, 2010 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-20739388
14.
Phase 1 study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumors.
Clin Cancer Res
; 16(11): 3044-56, 2010 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-20501621
15.
Identification of three loci affecting HDL-cholesterol levels in a screen for chemically induced recessive mutations in mice.
J Lipid Res
; 50(3): 534-545, 2009 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-18974039
16.
New variants in the Enpp1 and Ptpn6 genes cause low BMD, crystal-related arthropathy, and vascular calcification.
J Bone Miner Res
; 24(9): 1552-64, 2009 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-19419305
17.
Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors.
J Clin Oncol
; 25(17): 2369-76, 2007 Jun 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-17557949
18.
Anti-Epo receptor antibodies do not predict Epo receptor expression.
Blood
; 107(5): 1892-5, 2006 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-16249375
19.
Prediction of nephrotoxicant action and identification of candidate toxicity-related biomarkers.
Toxicol Pathol
; 33(3): 343-55, 2005.
Artigo
em Inglês
| MEDLINE | ID: mdl-15805072